Skip to content
Screener

TransMedics Group, Inc. TMDX Lung Product — Revenue

Other product segments

Liver Product
$138.98M+27.7%
Heart Product
$30.87M+3.5%

Similar metrics at other companies

GigaCloud Technology logo
GCTProduct revenues — Revenue
$290.82M+28.9%
Nine Energy Service logo
NINEProduct revenues — Revenue
$45.59M+23.1%
Ondas, Inc. logo
ONDSProduct Revenue — Revenue
$38.37M+1,090%
RFL
RFLProduct Revenue — Revenue
$89K-63.4%
AMC Robotics Corporation logo
AMCIProduct Revenue — Revenue
$586.62K-68.5%
ROC
ROCProduct Revenue — Revenue
$2.32M-4.7%

Other financials

Income statement

See full
Revenue$173.9M+21.2%
Gross profit$101.2M+14.7%
Operating income$13.3M-51.5%
Net income$7.3M-71.5%
EPS (diluted)$0.20-71.4%

Balance sheet

See full
Cash & equivalents$461.7M+48.9%
Total debt$409.9M+505%
Total equity$494.0M+85.5%
Total assets$1.4B+71.3%

Cash flow

See full
Operating cash flow$24.5M+959%
CapEx$36.7M+35.6%
Free cash flow-$12.1M+59.4%

Valuation

See full
Market cap$2.78B-31.3%
Enterprise value$2.73B-26.6%
P/E16.2×-40.3×
P/S4.4×-3.2×

Profitability

See full
Gross margin59.1%-0.4pp
Operating margin14.9%+4.1pp
Net margin27%+17.0pp
FCF margin23.8%

Returns & leverage

See full
Return on equity45.2%+22.2pp
Debt / equity0.8×+0.6×
Current ratio6.7×-2.4×

Where this comes from

Reported directly by TransMedics Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: TransMedics Group, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-206453
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Revenue:
Net product revenue$107,972$88,234
Service revenue65,96155,303
Total revenue173,933143,537
Cost of revenue:
Cost of net product revenue24,30816,312
Cost of service revenue48,46438,997
Total cost of revenue72,77255,309

Item 1. Financial Statements (Unaudited)

FAQ

What is TransMedics Group, Inc.'s lung product — revenue?
TransMedics Group, Inc. (TMDX) reported lung product — revenue of $2.82M in Q1 2026.
How has TransMedics Group, Inc.'s lung product — revenue changed year-over-year?
TransMedics Group, Inc.'s lung product — revenue decreased by 29.6% year-over-year, from $4.01M to $2.82M.
What is the long-term trend for TransMedics Group, Inc.'s lung product — revenue?
Over 4 years (2021 to 2025), TransMedics Group, Inc.'s lung product — revenue has grown at a 8.6% compound annual growth rate (CAGR), from $10.67M to $14.86M.
What does lung product — revenue mean?
This metric represents the total gross sales generated from the sale and service of lung-specific organ perfusion and monitoring technologies. It serves as a key indicator of the company's market penetration and clinical adoption rates within the pulmonary transplant segment. Tracking this revenue stream helps investors assess the commercial success of the lung-focused product portfolio relative to broader organ transplant market demand.

Ask your AI about TransMedics Group, Inc.'s lung product — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude